InterMune ascends on Esbriet sales, Phase III progress
This article was originally published in Scrip
Executive Summary
InterMune's stock closed at its highest price this year after the company's second quarter earnings report suggested that everything finally is moving into place for the idiopathic pulmonary fibrosis (IPF) drug Esbriet (pirfenidone).